Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Zafgen Inc    ZFGN

ZAFGEN INC (ZFGN)
Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 08/18 09:59:43 pm
3.47 USD   +0.58%
08/11 ZAFGEN : Reports Second Quarter 2017 Financial Results
08/09 ZAFGEN : reports 2Q loss
08/08 ZAFGEN, INC. (N : ZFGN) Files An 8-K Results of Operations and Finan..
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/14/2017 08/15/2017 08/16/2017 08/17/2017 08/18/2017 Date
3.38(c) 3.41(c) 3.48(c) 3.45(c) 3.47 Last
62 270 92 745 48 460 86 343 114 197 Volume
-0.59% +0.89% +2.05% -0.86% +0.58% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -59,4 M
Net income 2017 -60,5 M
Finance 2017 75,6 M
Yield 2017 -
Sales 2018 -
EBIT 2018 -70,0 M
Net income 2018 -71,0 M
Finance 2018 119 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 0
EV / Sales2018 0
Capitalization 94,8 M
More Financials
Company
Zafgen, Inc. is a biopharmaceutical company, which is engaged in the development of anti-obesity therapeutics that restores normal fat metabolism and regulatory pathways.Its product: Beloranib, which is under phase 2 clinical development as a treatment for obesity and hyperphagia in Prader-Willi... 
More about the company
Latest news on ZAFGEN INC
08/11 ZAFGEN : Reports Second Quarter 2017 Financial Results
08/10 ZAFGEN : Findings from Zafgen, Inc. Broaden Understanding of Obesity (A randomiz..
08/09 ZAFGEN : Management's Discussion and Analysis of Financial Condition and Results..
08/09 ZAFGEN : reports 2Q loss
08/08 ZAFGEN, INC. : Results of Operations and Financial Condition, Financial Statemen..
08/08 ZAFGEN, INC. (NASDAQ : ZFGN) Files An 8-K Results of Operations and Financial Co..
08/08 Zafgen Reports Second Quarter 2017 Financial Results
08/08 ZAFGEN INC : Investor Network: Zafgen, Inc. to Host Earnings Call
08/02 Zafgen to Present at the Canaccord Genuity 37th Annual Growth Conference
08/01 Zafgen to Host Conference Call to Discuss Second Quarter 2017 Financial Resul..
More news
Sector news : Bio Therapeutic Drugs
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Bio Therapeutic Drugs
Latest Tweets
08/16Candriam Luxembourg S.C.A. Sells 40,000 Shares of Zafgen, Inc. $ZFGN  
08/12Zafgen, Inc. $ZFGN Upgraded to “Buy” at Zacks Investment Research  
08/12Zafgen upgraded by Zacks Investment Research to buy. $3.75 PT.  
08/11Leerink Swann Raises Zafgen Q3 2017 Earnings Estimates to ($0.54) Per Share (.. 
08/09BRIEF-Zafgen Inc files for a potential mixed shelf offering of up to $150 mln.. 
More tweets
Qtime:16
News from SeekingAlpha
08/09 Zafgen files for $150M mixed shelf offering
08/08 Zafgen, Inc. 2017 Q2 - Results - Earnings Call Slides
08/08 Zafgen's (ZFGN) CEO Tom Hughes on Q2 2017 Results - Earnings Call Transcript
08/08 Zafgen beats by $0.03
08/07 Notable earnings after Tuesday?s close
Chart ZAFGEN INC
Duration : Period :
Zafgen Inc Technical Analysis Chart | ZFGN | US98885E1038 | 4-Traders
Technical analysis trends ZAFGEN INC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 8,00 $
Spread / Average Target 132%
EPS Revisions
Managers
NameTitle
Thomas E. Hughes President, Chief Executive Officer & Director
Peter Barrett Chairman
Patricia L. Allen CFO, Treasurer & Principal Accounting Officer
Dennis D. Kim Chief Medical Officer
Bruce Lee Booth Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ZAFGEN INC8.49%95
AMGEN14.77%122 447
CELGENE CORPORATION10.22%99 812
GILEAD SCIENCES1.02%94 471
REGENERON PHARMACEUTICALS27.64%49 721
VERTEX PHARMACEUTICALS101.63%37 450